Genprex, Inc. 8-K

What Happened
Genprex, Inc. filed an 8-K on April 28, 2026 reporting that research collaborators will present positive preclinical data at the 2026 ASGCT Annual Meeting (May 11–15, Boston) showing its Pdx1/MafA diabetes gene therapy (PM, also called GPX-002) can reverse hyperglycemia in Type 2 diabetes mouse models. The company’s press release describes complete rescue of high-fat-diet (HFD)–induced hyperglycemia at four weeks after direct intrapancreatic AAV-8 delivery of Pdx1/MafA.

Key Details

• Study timing and model: eight-week-old male C57BL/6 mice were fed regular diet (RD) or high-fat diet (HFD) for 24 weeks before treatment; outcomes assessed at 2 and 4 weeks post-treatment.
• Treatment: intrapancreatic infusion of AAV-8 encoding Pdx1 and MafA under either a CMV promoter (global/islet targeting) or RIP promoter (β-cell–specific), versus control virus.
• Main results at 4 weeks: HFD mice treated with CMV-PM or RIP-PM showed reversal of hyperglycemia, improved ex‑vivo glucose‑stimulated insulin secretion (GSIS) to levels similar to RD mice, increased mature insulin granules by EM, and transcriptomic shifts indicating β‑cell maturation.
• Translational note: Genprex highlighted technical translatability to humans via endoscopic retrograde cholangiopancreatography (ERCP); the filing includes standard forward‑looking cautionary language referencing SEC risk disclosures.

Why It Matters
These are preclinical (mouse) results that suggest GPX-002 may improve β‑cell function and potentially provide long‑term glycemic control if translatable to humans. For investors, the data support continued development of Genprex’s diabetes program and may inform future clinical planning, but the filing emphasizes this is early-stage evidence and contains forward‑looking statements subject to risks described in Genprex’s SEC filings.